Bonnie Kaur

Join Dr. Bonnie Kaur, Assistant Professor of Neurology and Pediatrics, as she dives into the world of neurofibromatosis type 1 (NF1). She discusses the evolution of treatments, including the groundbreaking MEK inhibitors, selumetinib and mirdametinib, which show promise in halting tumor growth. Dr. Kaur shares insights on eligibility, potential side effects, and the impressive results from recent clinical trials. She also highlights emerging therapies and resources for patients, making it a must-listen for those interested in NF1 advancements.